From Dog

Vinorelbine ditartrate is a semisynthetic vinca alkaloid which acts as a tubulin-binding mitotic inhibitor[1].

This drug is used in chemotherapy for certain canine cancers, specifically pulmonary tumors as this drug targets this organ[2].

Its properties are similar to vincristine and is primarily used as an adjunct drug in mast cell tumors[3] and bronchial carcinoma[4].

Side-effects include neutropenia and gastroenteritis[4].

Recommended dose rate in dogs is 10 - 20 mg/m2 given orally or intravenously every 7 days[5].


  1. Lagas JS et al (2012) P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol Pharmacol 82(4):636-644
  2. Kobayashi S et al (1993) Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung 43(12):1367-1377
  3. Grant IA et al (2008) A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 22(2):388-393
  4. 4.0 4.1 Poirier VJ et al (2004) Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med 18(4):536-539
  5. Zhou XJ et al (1993) Pharmacokinetics of navelbine after oral administration in the dog and the monkey. Anticancer Drugs 4(4):511-515